Fluid Removal: Are We Any Wiser?

Journal of Cardiac Failure

Volumn 14, Issue 1, 2008, Pages 6-8

  Ghali, Jalal K ^a   Vaitkevicius, Peter ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ELECTROLYTE; FUROSEMIDE; LOOP DIURETIC AGENT; MAGNESIUM; NEUROHORMONE; PARATHYROID HORMONE; TOLVAPTAN;

BLOOD VESSEL REACTIVITY; CALCIUM URINE LEVEL; CONGESTIVE HEART FAILURE; EDITORIAL; ELECTROLYTE DISTURBANCE; HEART LEFT VENTRICLE FILLING PRESSURE; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MAGNESIUM URINE LEVEL; MORBIDITY; MORTALITY; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; SYSTOLIC HEART FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRAFILTRATION;

EDEMA, CARDIAC; FEMALE; FUROSEMIDE; HEART FAILURE; HUMANS; KIDNEY FUNCTION TESTS; MALE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; ULTRAFILTRATION;

EID: 38349185589     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2007.11.007     Document Type: Editorial

References (28)

1. Adams K.F., Fonarow G.C., Emerman C.L., LeJemtel T.H., Constanzo M.R., Abraham W.T., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale design and preliminary observations from the Acute Decompensated Heart Failure National Registry (ADHERE®). Am Heart J 149 (2005) 209-216
2. Solomon S.D., Dobson J., Pocock S., Skali H., McMurray J.J.V., Granger C.B., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 116 (2007) 1482-1487
3. Lucas C., Johnson W., Hamilton M.A., Fonarow G.C., Woo M.A., Flavell C.M., et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 140 (2000) 840-847
4. Weber K.T. Furosemide in the long term management of heart failure: the good, the bad and the uncertain. J Am Coll Cardiol 44 (2004) 1308-1310
5. McCurley J., Hanlon S., Shao-kui W., Wedam E., Michalski M., and Haigney M. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 44 (2004) 1301-1307
6. Philbin E.F., Cotto M., Rocco Jr. T.A., and Jenkins P.L. Association between diuretic use, clinical response and death in acute heart failure. Am J Cardiol 80 (1997) 519-523
7. Neuberg G.W., Miller A.B., O'Connor C.M., Belkin R.N., Carson P.E., Cropp A.B., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
8. Eshaghian S., Howrich T.B., and Fonarow G.C. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 97 (2006) 1759-1764
9. Faris R., Flather M.D., Purcell H., Poole-Wilson P.A., and Coats A.J.S. Diuretics for heart failure. Issue 1. art No.: CD003838. Cochrane Database of Systematic Reviews (2006) 10.1002/14651858.CDOO3838.pub2
10. Konstam M.A., Gheorghiade M., Burnett J.C., Grinfeld L., Maggioni A.P., Swedberg K., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 297 (2007) 1319-1331
11. Udelson J.E., Orlandi C., Ouyang J., Krasa H., Zimmer C.A., Frivoid G., et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: The ECLIPSE international multicenter randomized, placebo-controlled trial. J Card Fail 13 (2007) 793
12. Schiff G.D., Fung S., Speroff T., and McNutt R.A. Decompensated heart failure: symptoms, patterns of onset, and contributing factors. Am J Med 114 (2003) 625-630
13. Chaudhry S.I., Wang Y., Concato J., Gill T.M., and Krumholz H.M. Patterns of weight change preceding hospitalization for heart failure. Circulation 116 (2007) 1549-1554
14. Gerhardt R.E., Abdullah A.M., Mach S.J., and Hudson J.B. Isolated ultrafiltration in the treatment of refractory congestive heart failure. Arch Intern Med 139 (1979) 358-359
15. Bourge R.C., and Tallaj J.A. Ultrafiltration a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol 46 (2005) 2052-2053
16. Agostoni P., Marenzi G., Lauri G., et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency failure of furosemide to provide the same result. Am J Med 96 (1994) 191-199
17. Constanzo M.R., Guglin M.E., Saltzberg M.T., Jessup M.L., Bart B.A., Teerlink J.R., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49 (2007) 675-683
18. Schrier R.W. Role of diminished renal function in cardiovascular mortality marker or pathogenetic factor?. J Am Coll Cardiol 47 (2006) 1-8
19. Libetta C., Sepe V., Zucchi M., Pisacco P., and Cosmai L. Intermittent haemodiafiltration in refractory congestive heart failure: BNP and balance of inflammatory cytokines. Nephrol Dial Transplant 22 (2007) 2013-2019
20. Rogers H.L., Marshall J., Bock J., Dowling T.C., Feller E., Robinson S., et al. A randomized, controlled trial of the renal effect of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail 14 (2008) 1-5
21. Smith G.L., Vaccarino V., Kosiborod M., Lichtman J.H., Cheng S., Watnick S.G., et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail 9 (2003) 13-25
22. Shlipak M.G., Chertow G.C., and Massie B.M. Beware the rising creatinine level. J Card Fail 9 (2003) 26-28
23. Gottlieb S.S., Brater D.C., Thomas I., Havranck E., Bourge R., Goldman S., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
24. Marenzi G., Lauri G., Grazi M., Assanelli E., Campodonico J., and Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 38 (2001) 963-968
25. Boyle A., and Sobotka P.A. Redefining the therapeutic objective in decompensated heart failure: hemoconcentration as a surrogate for plasma refill rate. J Card Fail 12 (2006) 247-249
26. Paterna S., Di Pasquale P., Parrinello G., Amato P., Cardinale A., Follone G., et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2 (2000) 305-313
27. Givertz M.M., Massie B.M., Fields T.K., Pearson L.L., and Dittrich H.C. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 50 (2007) 1551-1560
28. Dittrich H.C., Gupta D.K., Hack T.C., Dowling T., Callahan J., and Thomson S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 13 (2007) 609-617